title: Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants.
abstract: CD47 transduces inhibitory signals through signal-regulatory protein α (SIRPα), a plasma membrane receptor expressed by macrophages. Many cancers upregulate CD47 to evade immunosurveillance. We have recently engineered SIRPα variants that potently antagonize CD47 for use as anticancer immunotherapeutics. These high-affinity SIRPα variants synergize with antineoplastic antibodies by lowering the threshold for macrophage-mediated destruction of malignant cells.
authors: Institute for Stem Cell Biology and Regenerative Medicine; Stanford University School of Medicine; Stanford, CA USA ; Ludwig Center for Cancer Stem Cell Research and Medicine; Stanford University School of Medicine; Stanford, CA USA ; Stanford Cancer Institute; Stanford University School of Medicine; Stanford, CA USA.
authors: Kipp
authors: K
authors: Weiskopf
authors: Aaron M
authors: AM
authors: Ring
authors: Peter J
authors: PJ
authors: Schnorr
authors: Jens-Peter
authors: JP
authors: Volkmer
authors: Anne Kathrin
authors: AK
authors: Volkmer
authors: Irving L
authors: IL
authors: Weissman
authors: K Christopher
authors: KC
authors: Garcia
keywords: CD47; SIRPa; antibody; cancer; immune checkpoint; immunotherapy; macrophage; molecular engineering; phagocytosis